mismatch repair deficiency
UK's NICE Recommends Approval of Opdivo, Yervoy for MSI-High, MMR-Deficient Colorectal Cancer
The combination treatment has already been approved in the US and recommended for approval in this setting in Europe.
EMA's CHMP Recommends Approval for BMS' Opdivo Plus Yervoy for Certain Colorectal Cancer Patients
The committee recommended the combination for patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer.
NICE Recommends Keytruda for Metastatic MSI-High, Mismatch Repair-Deficient Colorectal Cancer
The draft guidance recommends Merck's immunotherapy be available to patients in the UK with untreated MSI-high or dMMR colorectal cancer.
European Commission Approves GSK's Dostarlimab in Endometrial Cancer
The approval marks the first anti-PD1 antibody available in Europe to treat recurrent or advanced endometrial cancer.
FDA Approves GSK's Jemperli With Ventana CDx for dMMR Endometrial Cancer
The FDA also approved the Ventana MMR RxDx panel as a companion diagnostic to select endometrial cancer patients for treatment with dostarlimab.